Compare HCA Health Inc (HCA) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs Marsh & McLennan Companies, Inc. — how do they compare? HCA Health Inc trades at $443.69 (market cap $96.35B), while Marsh & McLennan Companies, Inc. trades at $176.51 (market cap $84.31B). The key difference: HCA Health Inc and Marsh & McLennan Companies, Inc. are close in size by market cap, and Marsh & McLennan Companies, Inc. pays the higher dividend (2.24%). Which is the better fit depends on your goals — on Pluang, investors hold HCA Health Inc for 76 Days and Marsh & McLennan Companies, Inc. for 109 Days on average.
| HCA | MRSH | |
|---|---|---|
Market Cap | $96.35B | $84.31B |
Volume | 1,079,453 | 3,948,947 |
Sector | Health | Financials |
52-Week High | $545.13 | $207.02 |
52-Week Low | $361.32 | $157.32 |
Typical Hold Time | 76 Days | 109 Days |
Enterprise Value | $146.88B | $104.99B |
Dividend Yield | 0.7% | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare (HCA) trades at $439.17, up 1.61% on the day, with a bullish technical signal and strong fundamentals. The stock shows consistent revenue growth, reaching $75.6B in 2025, and has beaten EPS estimates for three consecutive quarters. Analyst consensus is bullish with a $461.12 price target, supported by solid cash flow from operations of $12.64B and a net income margin of 8.77%.
The outlook remains positive given earnings momentum and operational efficiency, but risks include ongoing legal investigations and high debt levels. Upside potential exists if the company maintains its earnings beat streak and manages payer-mix challenges effectively.
Marsh (MRSH) trades at $173.66, up 1.11% today, with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with consistent revenue growth from $20.7B in 2022 to $27.0B in 2025, and net income reaching $4.16B. Recent acquisition of Accel Holdings (October 2026) enhances its insurance advisory footprint. Valuation metrics include a P/E of 21.2 and ROE of 25.72%, indicating efficient capital use. Cash flow remains positive with $486M net inflow in 2025.
Outlook is cautiously optimistic with a consensus price target of $202.71 (17% upside), though 65% of analysts rate Hold. Risks include rising debt-to-asset ratio (35.43% in 2024) and potential margin pressure as net income margin dips to 14.24% in 2026. The stock's proximity to resistance at $174 requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
